Oramed Pharmaceuticals
ORMP
22 hedge funds and large institutions have $5.61M invested in Oramed Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
16% more funds holding
Funds holding: 19 → 22 (+3)
22% less call options, than puts
Call options by funds: $62K | Put options by funds: $79K
50% less capital invested
Capital invested by funds: $11.1M → $5.61M (-$5.52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$118K |
| 2 |
TAM
Tocqueville Asset Management
New York
|
+$98.6K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$94.4K |
| 4 |
D.E. Shaw & Co
New York
|
+$70.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$45.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Greylin Investment Management
Orange,
Virginia
|
-$260K |
| 2 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$126K |
| 3 |
Citigroup
New York
|
-$24K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$16.4K |
| 5 |
Morgan Stanley
New York
|
-$9.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | +$658 | +100 | New |
|
ORMP Hedge Fund Activity: Q4 2014 in Review
22 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2014, worth a combined $5.61M — down 50% from $11.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ORMP positions and 4 closed out — a net gain of 5 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Stifel Financial, adding an estimated $118K. The largest seller was Greylin Investment Management, cutting an estimated $260K.
- 22 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2014, up from 19 in Q3 2014.
- Funds reported $5.61M of Oramed Pharmaceuticals stock for Q4 2014, down 50% quarter-over-quarter.
- 9 funds opened new Oramed Pharmaceuticals positions in Q4 2014 and 4 closed out, a net change of +5 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2014 was Stifel Financial, an estimated $118K added.
- The largest Oramed Pharmaceuticals seller in Q4 2014 was Greylin Investment Management, an estimated $260K sold.
Based on aggregated 13F filings for Q4 2014.